Search Within

Heiko Schoder

  1. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (75)
  2. Meeting Abstract (67)
  3. Research Letter (4)
Groups
  1. Center for Hematologic Malignancies (146)
  2. Molecular Imaging and Therapy Service (146)
  3. Radiology, Department of (146)
  4. Department of Medicine (141)
  5. Hematologic Malignancies, Division of (135)
  6. Lymphoma (128)

More Groups

People
  1. Andrew Zelenetz (66)
  2. Alison Moskowitz (59)
  3. David Straus (56)
  4. Ariela Noy (55)
  5. Maria Palomba (53)
  6. Paul Hamlin (51)

More People

Years
  1. 2025 (5)
  2. 2024 (10)
  3. 2023 (17)
  4. 2022 (7)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Blood (49)
  2. Journal of Clinical Oncology (17)
  3. Hematological Oncology (11)
  4. International Journal of Radiation Oncology, Biology, Physics (7)
  5. Blood Advances (6)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. American Society of Clinical Oncology (17)
  3. Wiley Blackwell (14)
  4. Elsevier Inc. (8)
  5. Nature Publishing Group (6)
  6. Springer (6)

More Publishers

Results (146)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab
    Research Letter

    Stuver, R.; Vardhana, S. A.; Bedmutha, A.; Chan, K. K.; Mirtcheva-Trocheva, R.; Nosov, A.; Schöder, H.; Moskowitz, A.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • 18F-FDG PET/CT features as potent imaging biomarkers of efficacy and toxicity in large-B-cell lymphoma treated with CAR-T cell therapy
    Meeting Abstract

    Leithner, D.; Flynn, J. R.; Mauguen, A.; Devlin, S. M.; Fei, T.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M. E.; Lafontaine, D.; Michaud, L.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications
    Journal Article

    Kurtz, K.; Eibler, L.; Dacek, M. M.; Carter, L. M.; Veach, D. R.; Lovibond, S.; Reynaud, E.; Qureshy, S.; McDevitt, M. R.; Bourne, C.; more...
    Theranostics (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
    Journal Article

    Michaud, L.; Bantilan, K.; Mauguen, A.; Moskowitz, C. H.; Zelenetz, A. D.; Schöder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save